<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D3148B85-DDDD-492E-A9BD-12CA7827843B"><gtr:id>D3148B85-DDDD-492E-A9BD-12CA7827843B</gtr:id><gtr:firstName>Daljit</gtr:firstName><gtr:surname>Kaur</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_qA137867"><gtr:id>3EFBDCCD-ADAA-4C2E-8CE0-EC45E616EBDE</gtr:id><gtr:title>Clinical Trials Advisory and Awards Committee (CTAAC)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_qA137867</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>In 2002 CR-UK established the Clinical Trials Advisory and Awards Committee (CTAAC) to streamline and speed-up the peer review process of cancer trial proposals. The Committee reviews proposals coming from academia and recommends their suitability for funding or endorsement (access to NCRN recourses). The main foci are late phase clinical trials, such as phase III therapeutic clinical trials and some large phase II therapeutic clinical trials. CTAAC meets three times a year, at which clinical trial proposals are reviewed and judged on the basis of scientific excellence and clinical relevance. CTAAC will initially review proposals for cancer trials as outline applications. If the outline application is successful a full application will be invited which will be reviewed and discussed by CTAAC at a subsequent meeting. If the proposal is successful, funding will then be provided via CR-UK, with additional support provided via the NCRN funded networks. It should be noted that CTAAC considers both outline and full applications at each meeting. To be eligible to apply to CTAAC, the applicant must be from a UK university, clinical centre, or clinical trials unit. Funding is provided for clinical trials that are up to 10 years in duration and are usually at a level of approximately.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1067670</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_qA137867</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>61645070-5FD7-4854-9441-A8EB3A8B21BA</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>7.4  Resources and infrastructure (disease management)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>B3B786B2-60C5-4A01-808F-859CEE871296</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>8.5  Resources and infrastructure (health services)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>